Cellectar Biosciences, Inc. Share Price
NASDAQ: CLRB | Micro CapCellectar Biosciences, Inc. Stock Performance
Open $2.54 | Prev. Close $2.60 | Circuit Range N/A |
Day Range $2.53 - $2.54 | Year Range $2.20 - $6.16 | Volume 256 |
Average Traded $2.54 |
Cellectar Biosciences, Inc. Share Price Today
As of 9 August 2026, Cellectar Biosciences, Inc.'s share price is $2.48. The stock opened at $2.54, compared to its previous close of $2.60. During today's trading session, Cellectar Biosciences, Inc.'s share price traded between $2.53 and $2.54, with an average price of $2.54. Over the past 52 weeks, the stock has recorded a high of $6.16 and a low of $2.20. In terms of performance, Cellectar Biosciences, Inc.'s share price has declined by 25.97% over the last six months and is down 49.59% on a year-on-year basis.
Cellectar Biosciences, Inc. Share Price Chart
Cellectar Biosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $6.47M | PE Ratio (TTM) -0.30 | Dividend Yield N/A |
EPS (TTM) $-8.35 | Revenue (TTM) -$22.98M | Return On Equity (TTM) -255.25% |
Profit Margin 94.83% | Debt to Equity 0.56 | Quarterly Earnings Growth YoY 69.70% |
Cellectar Biosciences, Inc. Quarterly Profit & Loss
All figures in USD
Cellectar Biosciences, Inc. Annual Profit & Loss
All figures in USD
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.60 | $2.61 | -0.38% |
Jul 2026 | $2.83 | $2.62 | -6.43% |
Jun 2026 | $3.12 | $2.80 | -13.04% |
May 2026 | $2.64 | $3.22 | +22.43% |
Apr 2026 | $2.87 | $2.63 | +6.48% |
Mar 2026 | $3.02 | $2.47 | -26.27% |
Feb 2026 | $3.11 | $3.35 | +5.68% |
Jan 2026 | $3.56 | $3.17 | +9.31% |
Dec 2025 | $3.58 | $2.90 | -19.67% |
Nov 2025 | $3.26 | $3.61 | +6.49% |
Oct 2025 | $5.60 | $3.39 | -38.36% |
Sep 2025 | $4.89 | $5.50 | +11.79% |
CLRB Share Price FAQs
What is Cellectar Biosciences, Inc. share price today?
What is the 52 week high and 52 week low of Cellectar Biosciences, Inc. stock?
What is CLRB's market capitalisation today?
What is CLRB's net income for the last quarter?
What is the 5 year returns of CLRB?
What is the high & low stock price of CLRB today?
Can I buy CLRB shares in India?